THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST IN PROGRESS ON HIV THERAPEUTIC VACCINE
THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST
IN PROGRESS ON HIV THERAPEUTIC VACCINE
SAN DIEGO, Nov. 13 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) commented today on the recent interest in progress on HIV therapeutic vaccines in clinical studies and on yesterday's FDA Advisory Committee meeting discussing surrogate end- points in HIV therapies.
In conjunction with Rhone-Poulenc Rorer Inc. (NYSE: RPR), Immune Response is conducting Phase II/III clinical trials on an HIV therapeutic vaccine. These double-blind, placebo-controlled studies began in September 1990 and are scheduled to conclude in late 1992. To date, these and other studies indicate that the product appears safe and well tolerated.
As Immune Response has previously stated, until these studies are completed, the company will not have any clear indication of whether or not the product appears to be effective in preventing the transition to AIDS in seropositive patients. The studies are designed to capture changes in viral burden, T-cell counts and clinical end points. Consistent with the opinions expressed in yesterday's FDA Advisory Committee meeting, all of these end-points should be considered in the evaluation and ultimate approval of immunotherapeutics.
The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
/CONTACT: Steven L. Basta, investor relations, or Charles J. Cashion, VP-Finance of The Immune Response Corporation, 619-431-7080/
(IMNR RPR) CO: The Immune Response Corporation; Rhone-Poulenc Rorer Inc. ST: California IN: MTC SU: CH-JL -- SD004 -- 4031 11/13/91 14:29 EST